Compare Stocks: LRMR, ZYME, AAPG, and SNDX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$17.81 -6.3%	$18.17	$16.36 ▼ $48.45	$1.66B	0.1	6,753 shs	4,101 shs
LRMR Larimar Therapeutics	$4.16 -3.8%	$3.76	$2.71 ▼ $6.42	$431.63M	0.81	2.78 million shs	205,085 shs
SNDX Syndax Pharmaceuticals	$19.89 +0.7%	$20.65	$12.99 ▼ $25.59	$1.76B	0.4	1.60 million shs	223,947 shs
ZYME Zymeworks	$25.85 +2.1%	$24.06	$13.48 ▼ $29.75	$1.84B	1.15	664,294 shs	122,372 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	-3.42%	-2.58%	-2.88%	-4.16%	-59.55%
LRMR Larimar Therapeutics	-0.92%	+7.73%	+16.76%	+29.73%	+7.73%
SNDX Syndax Pharmaceuticals	-0.40%	-2.99%	-13.33%	+2.07%	+25.54%
ZYME Zymeworks	+0.76%	+4.76%	+4.63%	+3.73%	+76.25%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$17.81 -6.3%	$18.17	$16.36 ▼ $48.45	$1.66B	0.1	6,753 shs	4,101 shs
LRMR Larimar Therapeutics	$4.16 -3.8%	$3.76	$2.71 ▼ $6.42	$431.63M	0.81	2.78 million shs	205,085 shs
SNDX Syndax Pharmaceuticals	$19.89 +0.7%	$20.65	$12.99 ▼ $25.59	$1.76B	0.4	1.60 million shs	223,947 shs
ZYME Zymeworks	$25.85 +2.1%	$24.06	$13.48 ▼ $29.75	$1.84B	1.15	664,294 shs	122,372 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	-3.42%	-2.58%	-2.88%	-4.16%	-59.55%
LRMR Larimar Therapeutics	-0.92%	+7.73%	+16.76%	+29.73%	+7.73%
SNDX Syndax Pharmaceuticals	-0.40%	-2.99%	-13.33%	+2.07%	+25.54%
ZYME Zymeworks	+0.76%	+4.76%	+4.63%	+3.73%	+76.25%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.20	Buy	$46.43	158.08% Upside
LRMR Larimar Therapeutics	3.10	Buy	$11.67	177.71% Upside
SNDX Syndax Pharmaceuticals	2.85	Moderate Buy	$41.91	110.81% Upside
ZYME Zymeworks	2.82	Moderate Buy	$40.75	57.55% Upside

Current Analyst Ratings Breakdown

Latest LRMR, ZYME, AAPG, and SNDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	SNDX Syndax Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$44.00 ➝ $40.00
8/10/2026	ZYME Zymeworks	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00 ➝ $44.00
8/10/2026	ZYME Zymeworks	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/7/2026	ZYME Zymeworks	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$46.00
8/7/2026	ZYME Zymeworks	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$37.00 ➝ $40.00
8/7/2026	ZYME Zymeworks	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$31.00 ➝ $32.00
8/5/2026	ZYME Zymeworks	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$46.00 ➝ $51.00
8/5/2026	SNDX Syndax Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/5/2026	LRMR Larimar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$12.00 ➝ $11.00
8/5/2026	SNDX Syndax Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$40.00 ➝ $38.00
7/28/2026	SNDX Syndax Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$82.10M	20.46	N/A	N/A	$2.04 per share	8.82
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$0.94 per share	N/A
SNDX Syndax Pharmaceuticals	$172.35M	10.22	N/A	N/A	$0.74 per share	26.86
ZYME Zymeworks	$37.13M	49.43	N/A	N/A	$3.59 per share	7.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	-$177.71M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	-$165.67M	-$1.95	N/A	N/A	N/A	N/A	-137.39%	-97.65%	11/5/2026 (Estimated)
SNDX Syndax Pharmaceuticals	-$285.42M	-$2.51	N/A	N/A	N/A	-87.52%	-372.94%	-39.11%	11/2/2026 (Estimated)
ZYME Zymeworks	-$81.13M	-$2.02	N/A	646.63	N/A	-405.31%	-72.30%	-37.18%	11/5/2026 (Estimated)

Latest LRMR, ZYME, AAPG, and SNDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2026	Q2 2026	ZYME Zymeworks	-$0.5620	-$0.62	-$0.0580	-$0.62	$4.54 million	$3.23 million
8/4/2026	Q2 2026	LRMR Larimar Therapeutics	-$0.3815	-$0.30	+$0.0815	-$0.30	N/A	N/A
8/4/2026	Q2 2026	SNDX Syndax Pharmaceuticals	-$0.4477	-$0.55	-$0.1023	-$0.55	$79.36 million	$72.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	0.57	1.79	1.77
LRMR Larimar Therapeutics	N/A	4.70	4.70
SNDX Syndax Pharmaceuticals	38.95	6.77	6.44
ZYME Zymeworks	N/A	6.32	6.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
LRMR Larimar Therapeutics	91.92%
SNDX Syndax Pharmaceuticals	N/A
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
LRMR Larimar Therapeutics	4.00%
SNDX Syndax Pharmaceuticals	4.80%
ZYME Zymeworks	33.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	600	93.39 million	N/A	N/A
LRMR Larimar Therapeutics	30	103.88 million	99.73 million	Optionable
SNDX Syndax Pharmaceuticals	110	88.61 million	84.36 million	Optionable
ZYME Zymeworks	460	70.96 million	47.18 million	N/A

LRMR, ZYME, AAPG, and SNDX Headlines

Recent News About These Companies

Truist Financial Keeps Their Buy Rating on Zymeworks (ZYME)

August 14, 2026 | theglobeandmail.com

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME) and Edgewise Therapeutics (EWTX)

August 14, 2026 | theglobeandmail.com

FY2026 EPS Estimates for Zymeworks Cut by HC Wainwright

August 13, 2026 | americanbankingnews.com

Q3 Earnings Estimate for Zymeworks Issued By HC Wainwright

August 12, 2026 | marketbeat.com

TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks

August 11, 2026 | zacks.com

HC Wainwright Issues Negative Outlook for Zymeworks Earnings

August 11, 2026 | marketbeat.com

Zymeworks Steps Up Investor Outreach with September Conference Lineup

August 11, 2026 | tipranks.com

Zymeworks Announces Participation in Upcoming Investor Conferences

August 11, 2026 | financialpost.comF

Zymeworks Inc. to Participate in Upcoming Investor Conferences in September

August 11, 2026 | quiverquant.comQ

Zymeworks (NASDAQ:ZYME) Update Puts Antibody Strategy In Focus

August 9, 2026 | kalkinemedia.comK

Truist Financial Forecasts Strong Price Appreciation for Zymeworks (NASDAQ:ZYME) Stock

August 9, 2026 | americanbankingnews.com

Assenagon Asset Management S.A. Has $32.73 Million Stake in Zymeworks Inc. $ZYME

August 9, 2026 | marketbeat.com

Wells Fargo Remains a Buy on Zymeworks (ZYME)

August 8, 2026 | theglobeandmail.com

HC Wainwright Has Negative Outlook for Zymeworks Q3 Earnings

August 8, 2026 | americanbankingnews.com

Zymeworks (NASDAQ:ZYME) Issues Earnings Results, Misses Expectations By $0.05 EPS

August 7, 2026 | marketbeat.com

Zymeworks (NASDAQ:ZYME) Stock Price Expected to Rise, Truist Financial Analyst Says

August 7, 2026 | marketbeat.com

What is HC Wainwright's Forecast for Zymeworks Q2 Earnings?

August 7, 2026 | marketbeat.com

Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimates

August 6, 2026 | zacks.com

What is HC Wainwright's Estimate for Zymeworks Q3 Earnings?

August 6, 2026 | marketbeat.com

Segall Bryant & Hamill LLC Takes Position in Zymeworks Inc. $ZYME

August 6, 2026 | marketbeat.com

A Post Acquisition Look At Zymeworks

August 5, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LRMR, ZYME, AAPG, and SNDX Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$17.80 -1.20 (-6.29%)

As of 11:40 AM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Larimar Therapeutics NASDAQ:LRMR

$4.16 -0.17 (-3.82%)

As of 11:40 AM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Syndax Pharmaceuticals NASDAQ:SNDX

$19.89 +0.13 (+0.66%)

As of 11:21 AM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Zymeworks NASDAQ:ZYME

$25.85 +0.54 (+2.12%)

As of 11:40 AM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LRMR, ZYME, AAPG, and SNDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LRMR, ZYME, AAPG, and SNDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LRMR, ZYME, AAPG, and SNDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LRMR, ZYME, AAPG, and SNDX Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

Larimar Therapeutics NASDAQ:LRMR

Syndax Pharmaceuticals NASDAQ:SNDX

Zymeworks NASDAQ:ZYME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LRMR, ZYME, AAPG, and SNDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LRMR, ZYME, AAPG, and SNDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LRMR, ZYME, AAPG, and SNDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LRMR, ZYME, AAPG, and SNDX Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

Larimar Therapeutics NASDAQ:LRMR

Syndax Pharmaceuticals NASDAQ:SNDX

Zymeworks NASDAQ:ZYME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools